Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
Oral CGRP Inhibitor Is First For Dual Use
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
You may also be interested in...
Pfizer’s Blockbuster Migraine Portfolio Plan On Track With Zavzpret Approval
Pfizer plans to build on the momentum gained for its oral drug Nurtec ODT, now the leading CGRP inhibitor, with the intranasal Zavzpret, which will be priced in line with the rest of the class.
Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.